期刊文献+

结直肠癌患者术前血小板计数水平与肿瘤临床病理分期的关系 被引量:2

Association of platelet count and clinicopathological characteristics in colorectal cancer
下载PDF
导出
摘要 目的探讨结直肠癌患者术前血小板计数水平与肿瘤临床病理分期的关系。方法回顾性分析2015年1月至2016年12月安徽省肿瘤医院胃肠外科经组织病理学确诊的420例结直肠癌患者的临床资料,统计不同临床分期结直肠癌患者血小板增多症的发生率。结果结直肠癌血小板增多症发生率与肿瘤分化程度、淋巴转移、性别、年龄、肿瘤部位均无密切关系(P>0.05)。初诊时发现血小板增多症70例(16.67%),术后TNM I期70例,Ⅱ期99例,Ⅲ期217例,Ⅳ期34例,血小板增多症发生率依次为7.14%、14.14%、18.89%和29.41%,差异有统计学意义(P<0.05)。结论结直肠癌患者临床病理分期与血小板增多有密切关系。 ObjectiveTo explore the relationship between platelet count and colorectal cancer at the points of clinicatholocal stageand the prognosis.Methods The clinical data of420colorectal cancer patients from January2015to December2016were retrospectively analyzed.The frequency of patients with thrombocytosis in different clinicopathological stages was analyzed.Results Platelet count was associated with histological grade,distant metastasis,type,invasion depth and tumor stage(P<0.05),but not with degree of differentiation,lymph node metastasis,gender,age and tumor location(P>0.05).16.67%patients with colorectal cancer were accompanied with thrombocytosis.The frequency of patients with thrombocytosis in I(70cases),II(99cases),III(217cases),IV stage(34cases)were7.14%,14.14%,18.89%,29.41%,respectively and the difference was statistically significant(P<0.05).Conclusion There is a close relationship between platelet count and colorectal cancer.
作者 张俊 宁忠良 赵旭辉 魏忠 樊平 戴寅 谢钊 ZHANG Jun;NING Zhongliang;ZHAO Xuhui(Department of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital(West Branch of Anhui Provincial Hospital), Hefei 230031, China)
出处 《安徽医学》 2017年第12期1529-1532,共4页 Anhui Medical Journal
关键词 结直肠癌 临床病理特征 血小板增多症 Colorectal cancer Clinicopathological characteristics Thrombocytosis
  • 相关文献

参考文献5

二级参考文献131

  • 1李家增.止血异常与恶性肿瘤[J].血栓与止血学,2006,12(2):88-89. 被引量:29
  • 2徐志文 黄光武 等.头颈恶性肿瘤浸润转移的凝血纤溶因素[J].耳鼻咽喉:头颈外科,1999,6(5):318-320.
  • 3[82]Saltz L,Rubin M,Hochster H.Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR).Proceedings of the American Society of Clinical Oncology; 2001 May 12-15,San Francisco CA,USA.Vol 20 (3a),Abstract 7
  • 4[83]Vincenzi B,Santini D,Russo A,Silletta M,Gavasci M,Battistoni F,Di Cuonzo G,Rocci L,Gebbia N,Tonini G.Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.Ann Oncol 2006; 17:835-841
  • 5[84]Chong G,Cunningham D.The role of cetuximab in the therapy of previously treated advanced colorectal cancer.Semin Oncol 2005; 32:S55-S58
  • 6[85]Chung KY,Saltz LB.Antibody-based therapies for colorectal cancer.Oncologist 2005; 10:701-709
  • 7[86]Green LL.Antibody engineering via genetic engineering of the mouse:XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.J Immunol Methods 1999; 231:11-23
  • 8[87]Peeters M,Van Cutsem E,Siena S,et al.A phase 3,multicenter,randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts)with metastatic colorectal cancer (mCRC).Proceedings of the American Association for Cancer Research (AACR); 2006 Apr 1-5; Washington DC,USA.Abstract CP-1.Available from URL:http://aacr/org
  • 9[88]Tournigand C,Andre T,Achille E,Lledo G,Flesh M,Mery-Mignard D,Quinaux E,Couteau C,Buyse M,Ganem G,Landi B,Colin P,Louvet C,de Gramont A.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study.J Clin Oncol 2004; 22:229-237
  • 10[89]Goldberg RM,Sargent DJ,Morton RF,Fuchs CS,Ramanathan RK,Williamson SK,Findlay BP,Pitot HC,Alberts SR.A randomized controlled trial of fluorouracil plus leucovorin,irinotecan,and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol 2004; 22:23-30

共引文献39

同被引文献10

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部